NLRP3 inhib 
Welcome,         Profile    Billing    Logout  
 7 Companies  6 Products   6 Products   29 Diseases   11 Trials   763 News 


«12...109110111112113114115116117118119...134135»
  • ||||||||||  simvastatin / Generic mfg.
    Journal, IO Biomarker:  Inhibition of GGPPS1 attenuated LPS-induced acute lung injury and was associated with NLRP3 inflammasome suppression. (Pubmed Central) -  Jan 1, 2020   
    Compared with wild-type and simvastatin treated mice, the specific deletion of pulmonary GGPPS1 attenuated the severity of lung injury by inhibiting apoptosis of AECs...This effect might be attributed to the downregulation of GGPP levels. Our results suggested that inhibition of pulmonary GGPPS1 attenuated LPS-induced ALI, predominantly by suppressing the NLRP3 inflammasome through Rab10-mediated TLR4 replenishment.
  • ||||||||||  Journal:  ABRO1 promotes NLRP3 inflammasome activation through regulation of NLRP3 deubiquitination. (Pubmed Central) -  Jan 1, 2020   
    Furthermore, deficiency of BRCC3, the catalytically active component of BRISC, displays similar phenotypes to ABRO1 knockout mice. Our findings reveal an ABRO1-mediated regulatory signaling system that controls activation of the NLRP3 inflammasome and provide novel potential targets for treating NLRP3-associated inflammatory diseases.
  • ||||||||||  Preclinical, Journal:  A Traditional Clinic Chinese Medicine Prescription Qu-Zhuo-Tong-Bi (QZTB) Alleviates Gouty Arthritis in Model Rats. (Pubmed Central) -  Jan 1, 2020   
    QZTB (500 mg/kg) and the positive control drug meloxicam were administrated by gavages twice a day for 7 days before, or 3 days after, first MSU injection in different experiments, respectively...In addition, QZTB treatment significantly decreased both mRNA and protein levels of NLRP3, as well as the production of IL-1 and TNF-α in the ankle joint of model rats. Taken together, these results suggest that QZTB may be a promising herbal formula for the prevention and treatment of gouty arthritis in humans.
  • ||||||||||  Biomarker, Review, Journal:  Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases. (Pubmed Central) -  Dec 29, 2019   
    Other miRNAs like miR-155-5p modulate TLR-, IL-1R-, TNFR-, and IFNAR-mediated signaling pathways upstream of the inflammasomes. In this study, we discuss how a more detailed elucidation of miRNA-driven inflammasome regulation helps in understanding the molecular processes underlying immune-mediated human diseases, holds potential for the identification of biomarkers and may offer novel targets for the development of future therapeutics.
  • ||||||||||  Journal:  microRNA-520c-3p suppresses NLRP3 inflammasome activation and inflammatory cascade in preeclampsia by downregulating NLRP3. (Pubmed Central) -  Dec 29, 2019   
    In this study, we discuss how a more detailed elucidation of miRNA-driven inflammasome regulation helps in understanding the molecular processes underlying immune-mediated human diseases, holds potential for the identification of biomarkers and may offer novel targets for the development of future therapeutics. Collectively, miR-520c-3p could potentially inhibit NLRP3 inflammasome activation and inflammatory cascade in PE by downregulating NLRP3, highlighting the potential of miR-520c-3p as a therapeutic target for PE treatment.
  • ||||||||||  Journal:  Coriolus versicolor alleviates diabetic cardiomyopathy by inhibiting cardiac fibrosis and NLRP3 inflammasome activation. (Pubmed Central) -  Dec 28, 2019   
    In addition, high-glucose treatment induced cardiac fibrosis and increased cardiac inflammation in cardiac fibroblast cells, but these effects were ameliorated by CV extract treatment. Therefore, we conclude that the protective effect of CV on DCM is associated with the suppression of TGF-β1/Smad signaling and attenuation of NLRP3 inflammasome activation, suggesting that CV extract may be a potential therapeutic agent for DCM.
  • ||||||||||  Journal:  Pyroptosis in Antiviral Immunity. (Pubmed Central) -  Dec 26, 2019   
    Viruses have evolved their own mechanisms to modulate inflammasome signaling and pyroptosis. Here, we review the current literature regarding the role of pyroptosis in antiviral immune responses.
  • ||||||||||  Review, Journal:  NLRP3 inflammasome as a treatment target in atherosclerosis: A focus on statin therapy. (Pubmed Central) -  Dec 26, 2019   
    An increasing number of studies indicated NLRP3 inflammasome and their downstream mediators as important targets for statin drugs in inflammatory diseases. In this review, we discussed different aspect of the NLRP3 inflammasome signaling pathways and focused on the effect of statin drugs on NLRP3 inflammasomes in association to atherosclerosis in order to elucidate possible targets for future research and clinical settings.
  • ||||||||||  Journal:  TRPV1 mediates astrocyte activation and interleukin-1β release induced by hypoxic ischemia (HI). (Pubmed Central) -  Dec 26, 2019   
    TRPV1 promotes activation of astrocytes and release of astrocyte-derived IL-1β mainly via JAK2-STAT3 signaling and activation of the NLRP3 inflammasome. Our findings provide mechanistic insights into TRPV1-mediated brain damage and neurobehavioral disorders caused by neonatal HI and potentially identify astrocytic TRPV1 as a novel therapeutic target for treating HIE in the subacute stages (24 h).
  • ||||||||||  Preclinical, Journal:  Suppressive Effect of Huzhentongfeng on Experimental Gouty Arthritis: An In Vivo and In Vitro Study. (Pubmed Central) -  Dec 26, 2019   
    Moreover, HZTF also showed effects in cell-free and cell-base tests of antioxidant capacity. The results prove that HZTF possessed the potential preventive effect against gout arthritis, and the effect may be attributed to its preventing effect on neutrophil infiltration and proinflammatory cytokines secretion such as IL-1β, IL-6, and TNF-α which were caused by the activation of inflammasome.
  • ||||||||||  probenecid / Generic mfg.
    Journal:  NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP. (Pubmed Central) -  Dec 25, 2019   
    Mice were treated with MPTP/P, i.e., MPTP (25 mg/kg, s.c.) plus probenecid (250 mg/kg, i.p.) every 4 days, for ten times...Furthermore, the olfactory bulbs in MPTP/P-treated mice showed significantly increased levels of interleukin-1β (IL-1β), caspase-1, glial fibrillary acidic protein (GFAP), Toll receptor 4 (TLR4), phosphorylation of p65, as well as activated molecules of NOD-like receptor protein 3 (NLRP3) that were associated with neuroinflammation. Our results demonstrate that MPTP/P-caused olfactory bulb damage might be related to NLRP3-mediated inflammation.
  • ||||||||||  Journal:  Role of TXNIP/NLRP3 in sepsis-induced myocardial dysfunction. (Pubmed Central) -  Dec 25, 2019   
    The levels of TXNIP, NLRP3 and cleaved caspase‑1 and production of ROS were suppressed by siTXNIP, accompanied by increases in catalase and MnSOD. TXNIP/NLRP3 serves an important role in the development of sepsis‑induced myocardial damage.
  • ||||||||||  rosuvastatin / Generic mfg., AstraZeneca
    Clinical, Journal:  NLRP3 inflammasome expression in peripheral blood monocytes of coronary heart disease patients and its modulation by rosuvastatin. (Pubmed Central) -  Dec 25, 2019   
    The activation of NLRP3 inflammasome may be involved in the development of CHD, and rosuvastatin could attenuate the inflammatory process of atherosclerosis by downregulating NLRP3 expression and its downstream mediators. These findings indicated a potential role of NLRP3 in the pathogenesis and management of CHD, and also provided new insights into the mechanistic framework of rosuvastatin activity.
  • ||||||||||  Journal:  Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome. (Pubmed Central) -  Dec 25, 2019   
    NLRP3 inflammasome knockout blocked many of the observed microglial changes upon lipopolysaccharide, including alterations in microglial morphology and amyloid pathology. NLRP3 inhibition may thus represent a novel therapeutic target that may protect the brain from toxic peripheral inflammation during systemic infection.
  • ||||||||||  The complement system drives inflammatory memory via metabolic reprogramming of synovial fibroblasts (Promotion Hall KU Leuven) -  Dec 25, 2019 - Abstract #EWRR2020EWRR_79;    
    Depletion or genetic deficiency of complement component C3 abrogated the inflammatory tissue memory in vivo and normalized the aggressive SF phenotype. Our results suggest that inflammatory memory depends on intracellular complement C3 activation and metabolic reprogramming in SF, thus driving enhanced NLRP3 inflammasome activity.
  • ||||||||||  Journal:  NLRP3 inflammasome mediates angiotensin II-induced islet β cell apoptosis. (Pubmed Central) -  Dec 23, 2019   
    Ang II-induced apoptosis was inhibited after administration of the NLRP3 inhibitor MCC950, and TXNIP silencing could reduce the NLRP3 expression and apoptosis, while both effects of Ang II on TXNIP-NLRP3 and its apoptosis-inducing effect were inhibited by angiotensin II type I receptor (AT1R) blocker Telmisartan. Our results demonstrated that the TXNIP-NLRP3 inflammasome pathway mediated Ang II-induced INS-1 cell apoptosis and might hopefully become a novel target for the treatment of diabetes mellitus.
  • ||||||||||  Journal, IO Biomarker:  Atractylodin ameliorates lipopolysaccharide and d-galactosamine-induced acute liver failure via the suppression of inflammation and oxidative stress. (Pubmed Central) -  Dec 23, 2019   
    Moreover, our research showed that ACD could dramatically increase superoxide dismutase (SOD) and glutathione (GSH) production, and reduce COX-2, inducible nitric oxide synthase (iNOS), reactive oxygen species (ROS) and malondialdehyde (MDA) production through upregulating the expression of the anti-oxidative enzymes heme oxygenase-1 (HO-1) and quinone (NQO1), which were related to the induction of nuclear transcription factor 2 (Nrf2) nuclear translocation. These results indicated that ACD exhibited anti-inflammatory activity, which was associated with the inhibition of inflammatory mediator production via the downregulation of the NLRP3 inflammasome and TLR4-NF-κB/-MAPK signaling pathways, and the antioxidative effects of ACD were connected with GSH and SOD activation through upregulation of the Nrf2-mediated signaling pathways.
  • ||||||||||  Review, Journal:  The Role of the Cell Surface Mucin MUC1 as a Barrier to Infection and Regulator of Inflammation. (Pubmed Central) -  Dec 23, 2019   
    With respect to its physiological function in the mucosal environment, MUC1 has been demonstrated to play a dynamic role in protection of the host from infection by a wide variety of pathogens and to regulate inflammatory responses to infection. This review briefly summarizes the current knowledge and new findings regarding the structural features relating to the function of MUC1, its role as a protective barrier against pathogen invasion and mechanisms by which this cs-mucin regulates inflammation.
  • ||||||||||  Preclinical, Journal:  Puerarin inhibits vascular calcification of uremic rats. (Pubmed Central) -  Dec 23, 2019   
    In addition, we found that puerarin reduced IL-1β possibly through targeting NLRP3/Caspase1/IL-1β and NF-κB signaling pathways and inhibiting the generation of reactive oxygen species. Taken together, we demonstrated that puerarin has the capability of inhibiting vascular calcification in uremic rats by inhibiting inflammation.
  • ||||||||||  Journal:  Neisseria meningitidis-Induced Caspase-1 Activation in Human Innate Immune Cells Is LOS-Dependent. (Pubmed Central) -  Dec 23, 2019   
    While the lpxA mutant induced a priming response, measured as increased expression of NLRP3 and IL1B, the LOS-expressing FAM20 further increased this priming. We conclude that although non-LOS components of N. meningitidis contribute to the priming of the inflammasome activity, LOS per se is to be considered as the central component of N. meningitidis virulence, responsible for both priming and licensing of inflammasome activation.